In this issue of Conference Connect, we report some of the findings from further analyses of the landmark MAVORIC trial, presented at the EORTC – Cutaneous Lymphoma meeting (held in Marseille, France. October 2021).
An analysis of the efficacy of mogamulizumab (Poteligeo▼) in mycosis fungoides patients by blood tumour burden, including a comparison of time-to-response (TTR) between mycosis fungoides and Sézary syndrome (SS) yielded important positive results.
Interview and article by Christine Clark, PhD, FRPharmS.
The MAVORIC trial1 compared mogamulizumab with vorinostat in previously-treated cutaneous T-cell lymphoma (CTCL) – both mycosis fungoides (MF) and Sézary syndrome (SS). A post-hoc analysis of trial data showed that statistically significant improvements were seen in MF patients with blood involvement, according to a poster presented at the EORTC-CL meeting.
Interview and article by Christine Clark, PhD, FRPharmS.
Cutaneous T-cell lymphoma (CTCL) can have a profound impact on the health-related quality of life (HRQoL) and one of the contributory factors is intractable itching, according to Professor Pablo Ortiz-Romero (Dermatology Department, Hospital 12 de Octubre Medical School, Madrid Spain). Here he explains how patients describe the problem and how treatment with mogamulizumab is associated with improvements in HRQoL, particularly for those with blood involvement.
Interview and article by Christine Clark, PhD, FRPharmS.
Mogamulizumab is a humanised monoclonal antibody that selectively binds to C-C chemokine receptor 4 (CCR4). CCR4 is involved in trafficking of lymphocytes to skin and is expressed on the surface of tumour cells in certain T-cell malignancies.
Interview and article by Christine Clark, PhD, FRPharmS.
Cutaneous lymphomas (CLs) represent a rare and heterogeneous group of lymphomas that present in the skin without extracutaneous manifestations at the time of diagnosis.1 Mycosis fungoides (MF) and Sézary syndrome (SS) are the two best studied types of CTCL,2 together accounting for around two thirds of all CTCLs.3,4
Interview and article by Christine Clark, PhD, FRPharmS.
The impact of mycosis fungoides (MF) and Sézary syndrome (SS), and other cutaneous lymphomas in general, on the quality of life (QoL) is profound, according to Professor Margarida Lima (Haematology Department, University of Porto Hospital Centre). This is related to several factors, namely the cutaneous lesions themselves, the associated pruritus, secondary or opportunistic infections and constitutional symptoms.